Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Desipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 6/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 4/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 8/20 | 0.97 |
| ▸ | HTR2A | P28223 | 4/20 | 0.97 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.97 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.97 |
| ▸ | DRD2 | P14416 | 4/20 | 0.97 |
| ▸ | CHRM3 | P20309 | 4/20 | 0.97 |
| ▸ | HRH1 | P35367 | 4/20 | 0.97 |
| ▸ | DRD3 | P35462 | 4/20 | 0.97 |
| ▸ | SLC22A1 | O15245 | 3/20 | 0.97 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.97 |
| ▸ | ADRA2B | P18089 | 3/20 | 0.97 |
| ▸ | ADRA2C | P18825 | 3/20 | 0.97 |
| ▸ | HTR2C | P28335 | 3/20 | 0.97 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Desipramine SCHEMBL41992 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29364790 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL2944786 | 1.00 | SLC6A2 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL5072939 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL34384 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29379525 | 0.98 | SLC6A4 (1.00) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL29085912 | 0.97 | SLC6A4 (0.97) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL41993 | 0.95 | SLC6A4 (0.94) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL27517227 | 0.90 | SLC6A4 (0.83) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 | |
| Desipramine SCHEMBL28105338 | 0.90 | SLC6A4 (0.83) | SLC6A2CYP3A4PMP22SMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3191105-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | Braintree Laboratories, Inc. (US) | 2017-07-19 | — | — | EP | disclosed |
| WO-2016040733-A1 | SULFATE SALT SOLUTION LAXATIVE COMPOSITIONS AND METHODS OF USE THEREOF | BRAINTREE LABORATORIES, INC. (US) | 2016-03-17 | — | — | WO | disclosed |
| EP-2906208-A1 | THERAPEUTIC TREATMENT | Sears, Douglas (US) | 2015-08-19 | — | — | EP | disclosed |
| CN-1960781-A | Therapeutic combination for treatment of alzheimers disease | WARNER LAMBERT CO (US) | 2007-05-09 | — | — | CN | disclosed |
| EP-1737539-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | Warner-Lambert Company LLC (US) | 2007-01-03 | — | — | EP | disclosed |
| WO-2005099823-A1 | THERAPEUTIC COMBINATION FOR TREATMENT OF ALZHEIMERS DISEASE | WARNER-LAMBERT COMPANY LLC (US) | 2005-10-27 | — | — | WO | disclosed |
| US-6060642-A | TRANSGENIC MICE MODELS FOR GENE FUNCTION, WHEREIN THE TRANSGENIC MICE ARE CHARACTERIZED BY HAVING ALTERED SEROTONIN 5-HT6 RECEPTOR GENE FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-09 | — | — | US | disclosed |